Akums Drugs & Pharmaceuticals Ltd. has announced the launch of the world’s first Lasmiditan dispersible tablets, marking a significant advancement in the treatment of acute migraine. The DCGI-approved formulation introduces a patient-friendly approach designed to provide faster and more convenient relief during sudden migraine attacks.
Migraine: A Widespread Yet Under-treated Neurological Disorder
Headache disorders remain among the most common neurological conditions worldwide. However, they often remain under-recognised and inadequately treated. Migraine, in particular, is a debilitating neurovascular disorder characterised by recurrent episodes of throbbing, often one-sided headaches. These episodes frequently occur alongside symptoms such as nausea, vomiting, and sensitivity to light and sound.
Globally, more than one billion people live with migraine, making it one of the most prevalent neurological conditions. Consequently, improving access to effective and easy-to-administer treatments has become a critical priority in migraine care.
Dispersible Formulation Designed for Patient Convenience
To address the practical challenges patients face during migraine attacks, Akums developed a dispersible tablet formulation that focuses on ease of administration. Migraine episodes often involve nausea, gastric stasis, vomiting, and difficulty swallowing, which can make conventional tablets difficult to take.
Therefore, the new formulation can be mixed in a small amount of water, allowing patients to consume the medication more comfortably during an attack. This design improves treatment accessibility and patient compliance, particularly when symptoms make swallowing difficult.
Advanced Formulation Technology for Faster Relief
In addition to its patient-friendly format, the dispersible tablet incorporates a dual disintegration mechanism involving swelling and effervescence. This mechanism enables rapid dispersion of the tablet and facilitates faster therapeutic action during acute migraine episodes.
Furthermore, Akums has developed an advanced taste-masking technology to counter the intensely bitter taste of Lasmiditan. As a result, the formulation becomes more palatable, making it easier for patients to take the medication during severe attacks. Together, these technological improvements enhance the overall treatment experience and support better adherence to therapy.
Targeted Mechanism of Action: The Role of Lasmiditan
As per the press release, Lasmiditan belongs to the ‘ditans’ class of anti-migraine medications and functions as a highly selective serotonin 5-HT1F receptor agonist. Notably, the drug demonstrates a binding affinity that is more than 440 times higher for the 5-HT1F receptor compared to the 5-HT1B/1D receptors.
Because of this selectivity, Lasmiditan acts directly on sensory neurons involved in migraine pathways. Consequently, clinicians often describe it as a neurally active anti-migraine agent. The drug is indicated for the acute treatment of migraine with or without aura in adults, although it is not intended for preventive therapy.
A Next-Generation Option for Acute Migraine Management
By combining Lasmiditan’s targeted mechanism with a dispersible and easy-to-administer dosage form, Akums has introduced a next-generation option for managing acute migraine attacks. The formulation allows quick administration, rapid onset of action, and improved bioavailability, while also eliminating the need to swallow conventional tablets.
This approach is particularly beneficial for patients who experience nausea or vomiting during migraine episodes, enabling them to take medication more easily at the onset of symptoms.
Industry Perspective
Commenting on the development, Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd., said:
“Anyone who has experienced a migraine understands how suddenly and intensely it can disrupt everyday life. In those moments, patients need relief that is not only effective but also convenient to take. With the world’s first Lasmiditan dispersible tablets, we wanted to create a solution that addresses real patient challenges. The formulation disperses quickly in water, which is especially helpful during attacks when nausea or difficulty swallowing makes conventional tablets difficult to use. At Akums, we remain committed to developing thoughtful pharmaceutical innovations that combine strong science with practical patient needs, ultimately improving the treatment experience.”
Strengthening Patient-Centric Pharmaceutical Innovation
The introduction of Lasmiditan dispersible tablets represents an important advancement in migraine management through a patient-friendly dosage format. More broadly, the development reflects Akums’ commitment to delivering innovation-driven pharmaceutical solutions supported by advanced manufacturing capabilities, strong research and development, and patient-centric formulation design.
Through such initiatives, the company aims to improve treatment accessibility, patient compliance, and overall therapeutic outcomes in neurological care.